


S


Human Anti-SARS-CoV-2 Spike-RBD Bebtelovimab (LY-CoV1404 / LY3853113) Neutralizing mAb

Catalog No.	CPC539A CPC539B CPC539C	Quantity:	50 µg 100 µg 1.0 mg
Alternate Names:	Spike glycoprotein, Spike receptor binding domain, Spike-RB protein, Bebtelovimab, LY-CoV1404, LY3853113		
Description:	LY-CoV1404 (LY3853113) is a fully human anti-SARS-CoV-2 monoclonal antibody selected based on its potential to neutralize the virus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs (one of the major sites of infection). LY-CoV1404 potently neutralizes SARS-CoV-2 authentic virus and all known variants of concern including the B.1.617.2 (Delta) variant and variants of Omicron. Binding epitope on RBD of SARS-CoV-2 is rarely mutated. Bebtelovimab was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells.		
UniProt ID:	P0DTC2		
Origin:	Derived from plasma of a convalescent patient with Covid-19		
Specificity:	Recognizes SARS-CoV-2 Spike-RBD. The RBD positions comprising the LY-CoV1404 epitope are highly conserved.		
Bioactivity:	EC ₅₀ = 0.1121 for Omicron RBD		
Source:	XtenCHO		
Purity:	> 95% by reduced and non-reduced SDS-PAGE		
Isotype:	Human IgG1 kappa		
Clone:	LY-CoV1404 / LY3853113 (Bebtelovimab)		
Concentration:	1.0 mg/ml, lot specific		
Formulation:	Sterile-filtered PBS, pH 7.4 preservative free.		
Purification:	Protein A affinity chromatography		
Biological Activity:	EC ₅₀ = 0.1121 for Omicron RBD		
Applications:	Neutralization, Functional Assays		
Storage & Stability:	Stable at 2-8°C for 1 week or for up to 1 year at -20°C to -80°C. It is recommended to prepare single-use aliquots of undiluted product and store -20°C to -80°C. Avoid repeated freeze/thaw cycles.		





Coomassie blue staining non-reduced and reduced SDS-PAGE analysis



NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

